FSCN1 and esophageal squamous cell carcinoma: Therefore, the three-gene signature discovered in the present study, which is comprised of molecules within the EGFR/ERK/Fascin signaling pathway, may represent a useful preclinical model for improving ESCC treatment and clinical outcome.